A phase II study of bevacizumab in combination with definitive radiotherapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma: preliminary results of RTOG 0417.

[1]  B. Monk,et al.  Randomized comparison of weekly cisplatin or protracted venous infusion of fluorouracil in combination with pelvic radiation in advanced cervix cancer: a gynecologic oncology group study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Ricky T. Tong,et al.  Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer , 2004, Nature Medicine.

[3]  E. Hammond,et al.  Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) negatively affect overall survival in carcinoma of the cervix treated with radiotherapy. , 2003, International journal of radiation oncology, biology, physics.

[4]  Rakesh K. Jain,et al.  Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy , 2001, Nature Medicine.

[5]  P. Grigsby,et al.  Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  B N Bundy,et al.  Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  B N Bundy,et al.  Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. , 1999, The New England journal of medicine.

[8]  B N Bundy,et al.  Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. , 1999, The New England journal of medicine.

[9]  P J Eifel,et al.  Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. , 1999, The New England journal of medicine.

[10]  E. Ginzberg.  The uncertain future of managed care. , 1999, The New England journal of medicine.

[11]  A. Fyles,et al.  Oxygenation predicts radiation response and survival in patients with cervix cancer. , 1998, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[12]  J. Folkman,et al.  Blood Vessel Formation: What Is Its Molecular Basis? , 1996, Cell.

[13]  J. Folkman,et al.  The role of angiogenesis in tumor growth. , 1992, Seminars in cancer biology.

[14]  T R Fleming,et al.  One-sample multiple testing procedure for phase II clinical trials. , 1982, Biometrics.

[15]  Deborah Citrin,et al.  Combining radiotherapy and angiogenesis inhibitors: clinical trial design. , 2006, International journal of radiation oncology, biology, physics.

[16]  G. Thomas,et al.  Concurrent chemotherapy and radiation for locally advanced cervical cancer: the new standard of care. , 2000, Seminars in radiation oncology.

[17]  M. Volm,et al.  Interrelationships between microvessel density, expression of VEGF and resistance to doxorubicin of non-small lung cell carcinoma. , 1996, Anticancer research.